Scope, Claims, and Patent Landscape Analysis of U.S. Patent 6,162,463
What Does U.S. Patent 6,162,463 Cover?
U.S. Patent 6,162,463, issued on Dec. 19, 2000, is titled "Methods for treating neurodegenerative diseases". The patent primarily claims a method of treating neurodegenerative conditions through the administration of a specific class of compounds, namely monoamine oxidase inhibitors (MAOIs). The patent details narrow and broad claims covering both the compounds and their use in treating diseases such as Parkinson’s disease.
Patent Claims Breakdown
Independent Claims
- Claim 1: A method of treating Parkinson’s disease in a mammal, comprising administering an effective amount of a compound of the formula (I), which includes specific substituted phenyl derivatives.
- Claim 8: A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
Dependent Claims
- Claims specify variations of the compound structure, dosages, and methods of administration.
- Certain claims specify the compounds as inhibitors of monoamine oxidase B (MAO-B) activity.
Scope of Claims
The scope focuses narrowly on particular chemical structures, specifically certain substituted phenyl derivatives. The claims cover both the compounds’ synthesis and their therapeutic use. The patent explicitly claims methods to treat Parkinson's but hints at potential broader applications for other neurodegenerative diseases.
Patent Landscape
Priority and Related Patents
U.S. Patent 6,162,463 is part of a portfolio linked to Merck & Co., filed in early 1998, with priority claimed from earlier European patent applications. It is linked to patents and patent applications covering other MAOI compounds and methods.
Patent Family and Global Protection
The patent family includes filings in Europe (EP 908 066 B1), Japan, Canada, Australia, and other jurisdictions, with granted or pending statuses. These filings expand coverage to key markets and establish a broad protection perimeter for the compounds and their therapeutic uses.
Patent Citations and Influences
The patent cited prior art related to MAO inhibitors, including earlier patents on clinical compounds. Subsequent patents cite 6,162,463 as foundational in the field of MAOI-based neurodegenerative therapies, indicating its influence on drug development pipelines.
Patent Expiry and Market Implications
The patent's expiration date is Dec. 19, 2018, considering the 20-year term from filing (1998). This opens potential generic competition in markets where the patent was key for exclusivity, especially in the United States.
Competitive Landscape
Major pharmaceutical firms, including Roche, Bristol-Myers Squibb, and other biotech entities, have developed alternative MAOI or non-MAOI therapies. Patent strategies involve filing around structures, formulation patents, or new methods of administration to extend market exclusivity.
Broader Context in Neurodegenerative Disease Treatments
The patent covers a niche of MAOI-based therapies targeting Parkinson’s. Alternative therapeutic strategies have emerged, including dopamine replacement, cell therapy, and neuroprotective agents, shifting the patent's relevance in the larger neurodegenerative space.
Patent Limitations
- Narrow chemical scope: claims focus on specific substituted phenyl compounds, limiting the patent to particular chemical entities.
- Method-specific: the patent doesn’t broadly claim all MAOIs or all neurodegenerative treatments but rather specific methods and compounds.
- No data exclusivity: as a clinical trial or data protection patent, it doesn't confer exclusivity over new data, just the compound and method.
Opportunities for Generics and Competitors
Once expired, generic manufacturers can produce MAO-B inhibitors without infringing this patent. Companies could also develop novel compounds or delivery systems circumventing the patent claims.
Key Takeaways
- U.S. Patent 6,162,463 claims specific substituted phenyl derivatives for treating Parkinson’s disease.
- The patent’s scope centers on chemical structure and use, with limited breadth beyond those compounds.
- Patent family extends protection globally; expiry in 2018 allows generic competition.
- Strategic competitors have filed around the patent with alternative compounds, formulations, or methods.
- Clinical impact remains influenced by broader treatment options beyond MAOIs.
FAQs
1. Does U.S. Patent 6,162,463 cover all MAO inhibitors?
No. It specifically claims a subset of substituted phenyl derivatives used as MAO-B inhibitors for neurodegenerative diseases.
2. Can generic manufacturers produce the claimed compounds after 2018?
Yes, following patent expiration, generics can legally market these compounds unless other patents or exclusivities apply.
3. Do the claims cover administration methods?
Yes, specific claims include administration methods, dosages, and formulations for Parkinson’s treatment.
4. How broad is the patent’s chemical scope?
The patent covers particular substituted phenyl derivatives, which limits its scope to those structures rather than all MAOIs.
5. What is the patent landscape’s significance for the neurodegenerative field?
It represents a foundation for MAOI-based therapies but faces competition from newer modalities and patents covering alternative targets.
References
- U.S. Patent 6,162,463. (2000). Methods for treating neurodegenerative diseases.
- European Patent Office. (2001). EP 908 066 B1.
- Smith, J., & Lee, K. (2005). Patent strategies for neurodegenerative therapies. Journal of Patent Law, 12(3), 55-70.
- U.S. Patent and Trademark Office. Patent Expiration Database. (2023).
- World Intellectual Property Organization. Patent Landscape Report on MAOIs. (2019).
